title: Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice.
abstract: Tocilizumab (TCZ) and tumour necrosis factor inhibitors (TNFi) are recommended for the treatment of rheumatoid arthritis (RA) in patients with inadequate response (IR) to prior disease-modifying antirheumatic drugs (DMARDs). This retrospective analysis assessed the efficacy of TCZ and TNFi, alone or in combination with DMARDs, in 1603 patients with IR to previous treatment with either DMARDs (DMARD-IR) and/or TNFi (TNFi-IR), initiating treatment with TCZ or a TNFi, managed in routine clinical practice. Patients were grouped according to treatment history and treatment initiated: DMARD-IR patients initiating treatment with TCZ + DMARD (DMARD-IR TCZ) or TNFi + DMARD (DMARD-IR TNFi), DMARD-IR and/or TNFi-IR patients initiating treatment with TCZ monotherapy (TCZ mono) or TNFi monotherapy (TNFi mono), and TNFi-IR patients initiating treatment with TCZ + DMARD (TNFi-IR TCZ) or TNFi + DMARD (TNFi-IR TNFi). Patients initiating treatment with TCZ generally had more severe disease and longer disease duration compared with the corresponding TNFi group. Significantly more patients achieved remission (DAS28 ESR <2.6) in the TCZ groups compared with corresponding TNFi groups (DMARD-IR, TCZ 44.0 % vs. TNFi 29.6 %; monotherapy, TCZ 37.2 % vs. TNFi 30.2 %; TNF-IR, TCZ 41.3 % vs. TNFi 19.2 %; p < 0.001 for all comparisons). More patients achieved moderate-good responses (EULAR criteria) in the TCZ treatment groups (79-85 %) compared with TNFi treatment groups (65-81 %). Patient-reported outcomes showed greater improvements in TCZ compared with TNFi groups. In patients with inadequate response to DMARDs and/or TNFi treated in routine clinical practice, TCZ in combination with DMARDs or as monotherapy resulted in significantly more patients achieving remission and more marked improvements in patient-reported outcomes compared with TNF inhibitors.
authors: Medizinische Klinik mit Schwerpunkt Rheumatologie und klinische Immunologie, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany, backhaus@park-klinik.com.
authors: Marina
authors: M
authors: Backhaus
authors: Jörg
authors: J
authors: Kaufmann
authors: Constanze
authors: C
authors: Richter
authors: Siegfried
authors: S
authors: Wassenberg
authors: Anne-Eve
authors: AE
authors: Roske
authors: Peter
authors: P
authors: Hellmann
authors: Markus
authors: M
authors: Gaubitz
mesh_terms: D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; C502936:tocilizumab
references: J Rheumatol. 2009 Nov;36(11):2435-42
references: 19833759
references: N Engl J Med. 2000 Nov 30;343(22):1586-93
references: 11096165
references: Lancet. 2004 Feb 28;363(9410):675-81
references: 15001324
references: Arthritis Rheum. 2006 Jan;54(1):26-37
references: 16385520
references: Rheumatology (Oxford). 2006 Mar;45(3):325-31
references: 16287927
references: Ann Rheum Dis. 2010 Jan;69(1):88-96
references: 19297346
references: Ann Rheum Dis. 2010 Jun;69(6):964-75
references: 20444750
references: Mod Rheumatol. 2010 Aug;20(4):343-52
references: 20480201
references: Mod Rheumatol. 2010 Dec;20(6):531-8
references: 20574649
references: Arthritis Rheum. 2011 Mar;63(3):609-21
references: 21360490
references: Scand J Rheumatol Suppl. 2011;125:6-11
references: 21529304
references: Rheumatology (Oxford). 2011 Jul;50(7):1259-67
references: 21292734
references: Ann Rheum Dis. 2012 Feb;71(2):161-71
references: 21998122
references: Rheumatology (Oxford). 2012 Feb;51(2):338-46
references: 22096014
references: Rheumatology (Oxford). 2012 Jun;51 Suppl 4:iv14-20
references: 22685271
references: Z Rheumatol. 2012 Sep;71(7):592-603
references: 22930110
references: Ann Rheum Dis. 2013 Jan;72(1):43-50
references: 22562983
references: Arthritis Care Res (Hoboken). 2013 Mar;65(3):362-71
references: 22972745
references: Ann Rheum Dis. 2013 May;72(5):672-7
references: 22679306
references: Lancet. 2013 May 4;381(9877):1541-50
references: 23515142
references: Clin Rheumatol. 2013 Sep;32(9):1347-55
references: 23703358
references: Ann Rheum Dis. 2014 Jan;73(1):86-94
references: 23962455
references: Rheumatol Int. 2014 Jan;34(1):1-9
references: 23942828
references: Arthritis Rheum. 2006 Apr;54(4):1063-74
references: 16572441
references: Lancet. 2008 Mar 22;371(9617):987-97
references: 18358926
references: Bull NYU Hosp Jt Dis. 2008;66(2):77-85
references: 18537774
references: Rheumatology (Oxford). 2008 Jul;47(7):980-4
references: 18413345
references: Arthritis Rheum. 2008 Oct;58(10):2968-80
references: 18821691
references: Ann Rheum Dis. 2008 Nov;67(11):1516-23
references: 18625622
references: Ann Rheum Dis. 2009 Jan;68(1):63-8
references: 18375536